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Medical treatment for acute heart failure (AHF) has not changed substantially over the last four 
 
decades. Emergency department (ED)-based evidence for treatment is limited. Outcomes remain 
 
poor, with a 25% mortality or re-admission rate within 30 days post-discharge. Targeting 
 
pulmonary congestion, which can be objectively assessed using lung ultrasound (LUS), may be 
 




BLUSHED-AHF is a multicenter, randomized, pilot trial designed to test whether a strategy of 
 
care that utilizes a LUS-driven treatment protocol outperforms usual care for reducing 
 
pulmonary congestion in the ED. We will randomize 130 ED patients with AHF across 5 sites to: 
 
a) a structured treatment strategy guided by LUS vs. b) a structured treatment strategy guided by 
 
usual care. LUS-guided care will continue until there are ≤ 15 B-lines on LUS or 6 hours post 
 
enrollment. The primary outcome is the proportion of patients with B-lines ≤ 15 at the 
 
conclusion of 6 hours of management. Patients will continue to undergo serial LUS exams 
 
during hospitalization, to better understand the time course of pulmonary congestion. Follow up 
 
will occur through 90 days, exploring days-alive-and-out-of-hospital between the two arms. The study is 
registered on ClinicalTrials.gov (NCT03136198). 
 
In conclusion, if successful, this pilot study will inform future, larger trial design on LUS driven 
 
therapy aimed at guiding treatment and improving outcomes in patients with AHF. 
 
36 Introduction 
 37 Acute heart failure (AHF) is a major public health burden 1-4. Approximately 6 million 
 38 Americans have chronic HF, and over 870,000 people are newly diagnosed annually 1. In 2013, 
 39 over 30 billion dollars were spent on HF alone, with the majority of these costs due to AHF 
 40 hospitalizations 5. For patients aged 65 years and older, HF is the most common reason for 
 41 hospitalization 6. Within 30 days of hospital discharge, 25% of patients will be dead or re- 
 42 hospitalized 7, 8. 
 43 Pulmonary congestion is the primary reason that patients with HF seek emergency care 1, 
 44 9, 10. Decongestion is associated with improved outcomes 11, 12. Despite this, many patients 
 45 remain congested at time of discharge. 10, 11, 13, 14. This may be due to continued reliance on 
 46 traditional approaches to congestion assessment (i.e. signs and symptoms of HF), which lack 
 47 sensitivity and have poor inter-rater reliability 10, 13, 15, 16. 
 48 Because pulmonary decongestion is a vital treatment goal, a more reliable method of 
 49 assessment, able to be utilized by a broad range of practitioners, is needed. B-line assessment on 
 50 lung ultrasound (LUS) is an objective, easy-to-learn, quantitative measure of pulmonary 
 51 congestion. 16-20 Assessment for B-lines outperforms physical examination, chest radiography, 
 52 and brain natriuretic peptide (BNP) in the diagnosis of AHF 21. B-lines are a dynamic marker of 
 53 pulmonary congestion that clear in response to treatment, though studies have been small 22-25. 
 54 Persistence of B-lines after hospital discharge in patients with AHF is associated with a worse 
 55 prognosis, including a greater than five-fold risk of hospital re-admission and mortality 26-28. 
 56 The B-lines Lung Ultrasound Guided Emergency Department Management of Acute 
 57 Heart Failure (BLUSHED-AHF) pilot trial is an NHLBI funded study designed to test whether a 
 58 LUS-guided protocol, compared to structured usual care, will lead to more rapid resolution of 
59 pulmonary congestion. We hypothesize that a LUS-driven protocol for ED AHF management 
 60 will be feasible and will lead to a clinically significant reduction in pulmonary congestion (as 
 61 measured by B-lines) during the first 6 hours of management. We chose 6 hours to demonstrate 
 62 this proof-of-concept study of targeting B-lines. In addition, at the time of hospital discharge, we 
 63 hypothesize patients with persistent B-lines will have worse outcomes. This pilot trial will 
 64 inform a definitive outcomes study targeting B-lines both in the ED and during hospitalization. 
 65  
66 Methods 
 
67 Study Design and Population 
 68 BLUSHED-AHF is multi-center, prospective, randomized control trial. One hundred and 
 69 thirty patients will be enrolled from 5 EDs, in the United States. Eligibility criteria are listed in 
 70 Table 1. 
 71 Patients fulfilling enrollment criteria will be included after written informed consent. This 72 study has been approved by the Institutional Review Board at all study sites and registered on 
ClinicalTrials.gov (NCT03136198) 
 73  
74 Study Treatment 
 75 Enrolled patients will be randomized in a 1:1 fashion to LUS-guided strategy-of-care or 
 76 structured usual care. Randomization will occur using the REDCap randomization module. 
 77 Randomization block sizes of 2, 4, and 6 will be used, and stratified by site. The data 
 78 coordinating center will continuously monitor the recruitment until the targeted sample size is 
 79 reached. 
80 After initial ED evaluation and randomization, which includes a baseline screening LUS 
 81 exam and a baseline clinical assessment, patients will have two additional assessments during the 
 82 initial 6 hours of the protocol (Figure 1). 
 83 The first assessment will occur 2-4 hours after enrollment (T1). The second assessment 
 84 will occur 2-4 hours after the first assessment (T2), or prior to ED disposition for patients 
 85 discharged from the ED. If a patient is admitted to the hospital or an observation unit the second 
 86 assessment (T2) will occur at this location. These additional assessments will include both a LUS 
 87 performed by the study team and a clinical assessment performed by the treating physician. 
 88  
89 Clinical Assessment 
 90 Treating clinicians in both arms will be asked a series of standardized questions, listed in 
 91 Table 2, to determine whether their patient’s congestion has improved, and what, if any, methods 
 92 of assessment were used to derive their determination. 
 93  
94 Structured usual care 
 95 For patients randomized to structured usual care, the treating team will be blinded to LUS 
 96 assessments. Treatment decisions in the usual care arm will be guided solely by clinical re- 
 97 assessment. If the treating clinician feels that further treatment is indicated, then care will 
 98 continue based on the treatment protocol, Figure 1. If the treating clinician deems that the patient 
 99 has achieved adequate decongestion and no further treatment is indicated, then the treatment 
 100 algorithm will be halted; however, LUS assessments will continue per protocol. 
 101  
102 ED LUS-guided strategy-of-care 
103 Patients randomized to the LUS-guided strategy-of-care arm will have the 
 104 aforementioned clinical assessment and LUS exam performed. Clinicians in the LUS arm will be 
 105 instructed to administer further treatment as outlined in Figure 1, until there is a decrease in B- 
 106 lines on LUS to ≤ 15, 6 hours of care has been delivered, or the patient has been discharged. 
 107 Safety guidelines, such as significant drop in blood pressure or very brisk diuresis, are 
 108 highlighted for the investigators to consider when re-dosing medications per protocol. While we 
 109 will collect treating clinicians’ clinical assessments, the LUS arm treatment protocol is based 
 110 solely on the persistence of B-lines on LUS. Therefore, if the LUS shows ≤ 15 B-lines the 
 111 treatment algorithm will be stopped. In contrast, if the LUS shows >15 B-lines, algorithm guided 
 112 treatment continues based on Figure 1. 
 113  
114 During Hospitalization 
 115 Throughout hospitalization patients will have serial LUS and physical exam assessments 
 116 (taken from the medical record), (see Figure 2) regardless of treatment arm. Treating clinicians 
 117 will be blinded to LUS assessments performed. These follow-up assessments will inform future 
 118 studies and help determine if ongoing LUS monitoring throughout hospitalization provides 
 119 meaningful clinical information regarding pulmonary congestion. 
 120 Patients will be followed throughout their ED stay, hospital admission, and for 90-days 
 121 after hospital discharge (Figure 2). We will call patients at both 30 and 90 days post-discharge to 
 122 assess vital status, unscheduled healthcare visits and re-hospitalization. 
 123  
124 LUS Protocol 
 
125 Machine settings 
126 All enrolled patients will have serial LUS examinations performed using Zonare ZS3 or 
 127 Z One Pro (Mindray, Mountain View, CA) or Sonosite MTurbo (FUJIFilm Sonosite, Bothell, 
 128 WA) ultrasound machines with the curvilinear transducer. Ultrasound machine settings will be 
 129 standardized: depth of 18 centimeters, clip length 6 seconds, and tissue harmonics and multi- 
 130 beam former turned off. The gain will be adjusted to the individual patient so that the rib 
 131 shadows appear black and the pleural line with lung sliding are distinct. 
 132  
133 Image Acquisition 
 134 As patient positioning can affect B-line counts 29, all patients will be scanned in a semi- 
 135 upright position, with the head of the bed at 45 degrees. We will follow previously published 
 136 LUS scanning protocols 16 utilizing an 8-zone approach, see Figure 3. Videos will be acquired 
 137 with the probe in a transverse orientation, with the probe indicator facing the patient’s right side 
 138 and the probe face parallel to the adjacent ribs. Two additional videos, one on each side of the 
 139 chest, will be acquired in the mid-axillary line at the caudal portion of the chest to assess for the 
 140 presence and size of a pleural effusion. 
 141 In addition to the initial LUS examination, up to two additional LUS studies will be 
 142 performed within 6 hours of enrollment, if the patient remains in the ED. Repeat LUS 
 143 examinations will be performed daily until discharge or hospital day 7, whichever comes first. 
 144  
145 Sonographers and Pre-enrollment Training 
 146 Sonographers will range in experience level from novice to expert and will include 
 147 research associates, postgraduate year (PGY) 1-3 emergency medicine residents, emergency 
 148 ultrasound fellowship trained faculty, and non-ultrasound trained emergency medicine faculty. 
149 Research associates will be included in those that perform and interpret LUS exams because 
 150 LUS images are easy to acquire and interpret 16, 30, and a tool non-physicians are able to utilize 
 151 31. To ensure uniformity and reliability of LUS examinations, all sonographers will complete a 
 152 standardized ultrasound training course. This will include: 1) a 2-hour training session led by the 
 153 ultrasound site principal investigator consisting of didactics and image review to practice 
 154 counting B-lines; and 2) proctored hands-on scanning of patients with pulmonary congestion. To 
 155 be deemed proficient, sonographers must obtain ≥25 LUS videos that have been reviewed by the 
 156 ultrasound site principal investigator and have achieved an intraclass correlation >0.7. Over 90% 
 157 of the LUS videos will have to have B-lines. Twenty percent of these pre-study images will then 
 158 be reviewed by the LUS Core Lab. 
 159  
160 Quantifying B-lines 
 161 B-lines are vertical echogenic artifacts that originate from the pleural line, move with 
 162 respiration and extend to the bottom of the ultrasound screen 16, 17. In patients with more severe 
 163 pulmonary edema, B-lines may fuse together. 
 164 The total B-line count will be determined by summing the number of B-lines in each of 
 165 the 8 zones, while the probe is placed in a transverse orientation, to maximize the amount of 
 166 examined pleura. Each zone is given a B-line score of 0-20 based on the number of B-lines 
 167 counted in one respiratory cycle across the entire visualized scanning field. To quantify the 
 168 number of B-lines visualized in each zone, the intercostal space with the greatest number of B- 
 169 lines within each zone will be used for scoring. Discrete, narrow B-lines will be counted 
 170 individually. For those that are wide or fused together, the score will be determined by 
 171 multiplying the percentage of the intercostal space filled with confluent B-lines by 20, thereby 
172 giving a maximum total count of 20 B-lines per individual zone (i.e. if 50% of the screen is filled 
 173 with confluent B-lines, that will yield a score of 0.5 x 20 = 10 B-lines for that zone), see Figure 
 174 4. 
 175 If, within a single zone, only a pleural effusion is seen but no lung is visualized, a B-line 
 176 count of 0 will be assigned. If both lung and a pleural effusion are seen in the same intercostal 
 177 space, then sonographers will count the number of B-lines visualized, as described above. The 
 178 presence of pleural effusions will be assessed in each hemithorax in zone 4, with the probe held 
 179 in a coronal plane with the indicator pointed towards the patient’s axilla. Pleural effusions will be 
 180 graded as small, moderate or large. 
 181 B-lines will be counted upon completion of LUS exam by the sonographer who obtained 
 182 the images. Findings will be recorded on a standardized data collection form. Individual zones 
 183 and a composite B-line score will be recorded. 
 184  
185 Core Lab 
 186 A Core Lab, consisting of two independent physicians with expertise in LUS, but not 
 187 associated with one of the study sites, will individually review all images to assess for inter- 
 188 observer agreement. They will be blinded to study arm, patient information, sonographer 
 189 interpretation, study site, and the interpretation of the other expert reviewer. Only de-identified 
 190 images from all study sites will be sent to the Core Lab. Core Lab interpretation will be recorded 
 191 on a standardized data collection form. 
 192  
193 Laboratory Testing 
194 Patients will have labs collected at baseline (while the patient is in the ED), and on 
 195 hospital day 7 or day of discharge, whichever comes first. Standard venipuncture techniques or 
 196 other standard blood collection methods will be used in accordance with institutional standards. 
 197 Laboratory testing will be analyzed by the clinical lab at each respective institution for chemistry 
 198 and hemoglobin/hematocrit values. Amino-terminal pro B-type natriuretic peptide (NTproBNP) 
 199 and high-sensitivity (5th generation) troponin T (hsTnT) (Roche Diagnostics, Indianapolis, IN) 
 200 will be drawn within 6 hours of randomization as well as prior to discharge for study purposes 
 201 and will be analyzed centrally. 
 202  
203 Endpoints 
 204 The primary endpoint is the number of patients with ≤ 15 B-lines on LUS at 6 hours after 
 205 enrollment. Additionally, we will assess the exploratory endpoints listed in Table 3. Using these 
 206 endpoints we will be able to collect vital data on the ability of LUS to guide AHF management 
 207 through assessment of dynamic changes, and compare LUS to clinical assessment alone. In 
 208 addition, we will further examine the prognostic value of LUS B-lines, in comparison to 
 209 traditional assessments, including a preliminary determination of what B-line count warrants de- 
 210 escalation of care, and determining when patients are appropriate for discharge. Importantly, 
 211 assessment of B-lines during hospitalization combined with treatment will inform future study 
 212 design. As a pilot trial, we have focused on the ED and early phase of management. Future 
 213 studies may require LUS guidance throughout hospitalization. 
 214  
215 Safety Measures 
216 Mortality, unscheduled healthcare visits and re-hospitalization through 90 days will be 
 217 assessed for safety as well as efficacy signals. Hypotension and acute kidney injury within the 
 218 first 12 hours of therapy will also be assessed as safety endpoints. A systolic blood pressure that 
 219 drops below 100 mm Hg at any time or if a patient develops evidence of clinical hypoperfusion 
 220 (i.e. weakness, dizziness, etc) despite a systolic blood pressure > 100 mm Hg will be 
 221 immediately assessed and treated as needed. An independent data safety and monitoring board 
 222 will meet throughout the duration of the study and will oversee patient safety. 
 223  
224 Statistical Considerations 
 225 The primary hypothesis is that a higher proportion of LUS guided patients will be 
 226 decongested, defined as LUS B-lines ≤15, than usual care patients at 6 hours after enrollment. 
 227 Our preliminary data suggest that 25% of patients in the usual care arm will have ≤ 15 B lines at 
 228 the conclusion of ED AHF management. With 59 patients in each of the two arms, we will have 
 229 81% power to detect an effect size of 2 (i.e. 25% in the usual care versus 50% in the LUS-guided 
 230 strategy), where the type I error rate is set at 0.05 (two-sided). Considering a conservative 10% 
 231 drop-out rate, we will need a total of 130 subjects. We will perform two types of analysis, 
 232 intent-to-treat and per-protocol. The Full Analysis Set (FAS) will include all randomized 
 233 patients, which will be used in the intent-to-treat analysis where patients will be analyzed by the 
 234 group to which they were randomized. Analyses in the FAS will constitute the main efficacy 
 235 results for the primary and secondary study efficacy endpoints. The per-protocol analysis will be 
 236 performed using the Per-Protocol Set (PPS), a subset of the FAS excluding patients with major 
 237 protocol violations. The major protocol violations that will result in exclusion from the FAS 
 238 will be identified prior to unblinding the treatment assignments for final analysis. Patients will be 
239 analyzed in the treatment group to which they were randomized. Such results will complement 
 240 the primary efficacy analyses in the FAS. 
 241 Unless stated otherwise, two-sided p values < 0.05 will be considered statistically 
 242 significant, without adjustment of multiple comparisons. Statistical tables and listings and 
 243 analyses will be produced using SAS release 9.4 or later (SAS Institute, Inc, Cary, NC, USA) 
 244 or other validated statistical software. 
 245  
246 Analysis of the Primary Efficacy Endpoint: 
 247 The comparison of binary endpoints (B-lines ≤ 15) will be performed using Chi-square or 
 248 Fishers exact test, as appropriate. Potential covariates will also be considered in a logistic 
 249 regression setting to improve precision, which includes baseline co-morbidities, baseline 
 250 medications (in particular, guideline recommended therapies), in-hospital medications, baseline 
 251 renal function, serum sodium, natriuretic peptide levels, troponin levels, renal function, baseline 
 252 blood pressure, and discharge medications. Variables such as physical exam, other vital signs, 
 253 and hemoconcentration may also be included. For NT-proBNP, a percent change greater than 
 254 30% and its association with the primary endpoint will be analyzed. This is based on previous 
 255 work suggesting a 30% change was a key discriminatory threshold for mortality 33-35. For 
 256 hemoconcentration, any increase in either hematocrit and hemoglobin during hospitalization will 
 257 be considered positive 36. These covariates are known markers of risk and are standard of care 
 258 assessments for the vast majority of AHF admissions. Covariates with univariate significance 
 259 will be included together with the treatment indicator in a logistic regression model. We will 
 260 limit the number of covariates (including treatment indicator) such that there are at least 10 
 261 events per covariate. 
262  263   Analysis of the Exploratory Endpoints 
 264 Days alive and out of hospital (DAOOH) will be compared using t-test or Wilcoxon rank- 
 265 sum test, as appropriate. Alternatively, we will treat DAOOH as an ordinal outcome and use the 
 266 proportional odds (PO) regression model to compare the two arms. The PO regression allows for 
 267 adjustment of baseline covariates to enhance power. 
 268 We will examine the distribution of B-lines measurements stratified by pre-specified 
 269 outcomes. Both absolute number and relative change will be evaluated. Receiver operating 
 270 characteristic (ROC) curves will be plotted together and area under the curve (AUC) will be 
 271 calculated to understand the prediction performance of B-line measurement. Sensitivity, 
 272 specificity, positive and negative predictive values will be computed at a number of thresholds of 
 273 B-line measurements to understand the trade-off between false positive and false negative. 
 274 Confidence intervals of statistical measures will be constructed using the bootstrap method.37 
 275 Although 15 B-lines have been previously identified as a valid threshold, an alternative number 
 276 may be more useful in the ED setting. 
 277 For reproducibility analysis, generalized linear mixed-effects models will be fitted to 
 278 estimate the inter- and intra-observer variability, where both patients and observers are treated as 
 279 random effects. 
 280 We will compare parameters used to identify congestion, including B-line measurements 
 281 and other markers, such as physical exam, NTproBNP, eGFR, and hemoglobin/hematocrit. 
 282 Bootstrap method will be used for the comparison to account for correlations between the 
 283 markers and the B-line measurements. We will consider two strategies, logistic regressions and a 
284 tree-based method, to explore potential multivariate models for the prediction of 30 or 90-day 
 285 outcomes. 
 286 Models will be compared using the net reclassification rate 38, 39. Statistical inference of 
 287 the comparison will be performed using the bootstrap method. 
 288  
289 Discussion 
 290 Decongestion is a fundamental goal of AHF management. Failure to adequately 
 291 decongest is associated with worse outcomes. Despite its importance, a universal, robust, well- 
 292 validated method to assess and grade congestion with high inter-rater reliability does not exist.13 
 293 Traditional methods, such as body weight measurement, fluid balance, and physical exam 
 294 continue to form the foundation of congestion assessment.  Determination of whether alternative 
 295 methods of congestion assessment, such as LUS, perform better than accurately performed 
 296 traditional assessment is of critical importance. 
 297 The B-lines Lung Ultrasound Guided Emergency Department Management of Acute 
 298 Heart Failure (BLUSHED-AHF) Pilot Trial is designed to answer whether targeting B-lines – a 
 299 marker of pulmonary congestion – leads to more rapid resolution of pulmonary congestion 
 300 compared to usual care during the ED phase of management. Importantly, both arms will follow 
 301 the same treatment protocol. One limitation of this study design is the absence of a true ‘usual 
 302 care’ arm, where there is no standard treatment protocol. However, if LUS proved superior to 
 303 usual care, it could be fairly argued that LUS is less important than a standard treatment protocol. 
 304 As this is a pilot-trial, should targeting B-lines prove successful, a larger 3-arm study will be 
 305 considered in future studies. 
 306   Another limitation is that ultrasound is highly operator-dependent, which could alter the 
 307 sonographers acquisition and interpretation of LUS B-lines.  Nevertheless, ultrasound assessment 
 308 of B-lines is one of the easier ultrasound examinations to perform, and we designed a rigorous pre 
 
309 enrollment training program where each sonographer needs to achieve an intraclass correlation 
 310 >0.7 with an expert.  This is an effort to decrease variation in B-line quantification between 
 311 different sonographers. 
 312  Additionally, there is no way to blind the clinical status of the patient to the study team 313 performing LUS assessments. Despite this, all of the LUS performed for the study will be 314 reviewed by a Core Lab of two expert sonographers, blinded to study arm, to assess for 
agreement. 315 A recent systematic review on the value of LUS B-lines in assessment of pulmonary 
 316 congestion in patients with HF highlighted several gaps in the current literature 40. First, there are 
 317 no objective, qualitative data on what represents adequate B-line reduction in response to 
 318 standardized AHF treatment. Similarly, the time course of B-line resolution, based on treatment 
 319 of different HF phenotypes, is unclear. The current body of literature in this area is limited, and 
 320 lacks standardization with heterogeneity in imaging protocols, HF treatment and quantification 
 321 of B-lines 40. The BLUSHED-AHF pilot trial will provide further insight into each of these 
 322 questions. Other methods of decongestion assessment may also be valuable, such as 
 323 hemoconcentration or changes in natriuretic peptide levels, which we will analyze these as well. 
 324 These data will help inform future studies considering LUS as a standalone tool or as part of a 
 325 congestion score. 
 326  
327 Conclusions 
 328 Pulmonary decongestion is a crucial therapeutic goal in AHF. BLUSHED-AHF will test 
 329 a novel use of LUS to guide AHF management in the ED. This study will assess the incremental 
 330 value of LUS compared to clinical assessment alone. If successful, this pilot study will inform 
 331 future trials on LUS-driven therapy aimed at guiding acute treatment, and informing disposition 
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 504 Figure 1. Study treatment algorithm. 
 505 Figure 2. Trial Schematic and patient flow through study 
 506 Figure 3. Pictorial representation of the 8-zone scanning protocol. 
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 511 Supplemental video showing dynamic B-lines during patient inspiration and expiration. 
Table 1: Eligibility Criteria  
Inclusion Criteria Exclusion Criteria 
1) Age ≥ 21 years 
 
1) Chronic renal dysfunction, including 
ESRD or eGFR < 45ml//min/1.73m2    
2) Presents with shortness of breath at rest or 
with minimal exertion 
 
2) Shock of any kind. Any requirement for 
vasopressors or inotropes 
3) Clinical diagnosis of AHF and presence of 
> 15 total bilateral B-lines on initial LUS 
 
3) SBP < 100 or > 175mmHg 
4) History of chronic HF and any one of the 
following: 
i. Chest radiograph consistent with 
AHF  
ii. Jugular venous distension 
iii. Pulmonary rales on auscultation 
iv. Lower extremity edema 
 
4) Need for immediate intubation  
 5) Acute Coronary Syndrome (ACS) OR new 
ST-segment elevation/depression on EKG.  
(troponin elevation outside of ACS is 
allowed)  
 6) Fever >101.5ºF  
 7) End stage HF: transplant list, ventricular 
assist device 
 8) Anemia requiring transfusion 
 9) Known interstitial lung disease 
 10) Suspected acute lung injury or acute 
respiratory distress syndrome (ARDS) 
 11) Pregnant or recently pregnant within the 
last 6 months 
 
ESRD – end stage renal disease; eGFR – estimated glomerular filtration rate, SBP – systolic blood pressure; 
HF – heart failure 
 
Table 2: Clinical Assessment Form 
1. In your clinical opinion, is the patient still volume overloaded? 
2. If yes, do you think the patient warrants additional treatment now? 
3. The following questions will be asked of the physician: 
a. Did you assess jugular venous pressure (JVP)? 
i. If yes, did you measure it?  
1. If yes, record height in centimeters 
b. Did you auscultate the lungs? 
i. If yes, did you hear wheezing, rales, other breath sounds  
1. If yes for rales, did you assess how high up the lungs?  
a. If yes, then record how high up 
c. Did you listen to the heart?  
i. If yes, did you hear any extra heart sounds? 
1. If yes, ask what did you hear? 
d. Did you assess for peripheral edema?  
i. If yes, did you grade severity  
 
Table 3: Exploratory Endpoints  
Total DAOOH through 30 and 90 days post-
discharge 
Association of B-lines at discharge and 30 
and 90 day outcomes 
Change in biomarkers from presentation to 
pre-discharge 
Association of baseline, discharge, and 
change with 30 and 90 day outcomes 
Time to reach B-lines <15 B lines < 15 at 24 hours and at discharge 
Composite of 30-day all-cause mortality, 
cardiovascular (CV) re-hospitalizations, and 
CV emergency department (ED) revisits.  CV 
endpoints are defined according to the 2014 
ACC/AHA Key Data Elements and 
Definitions for Cardiovascular Endpoint 
Events.32 
Also for same endpoint, but through 90 days. 
All Cause readmissions, All cause ED re-
visits 
Change in physical exam findings and body 
weight from presentation to pre-discharge 
Description of ED pharmacologic treatment 
Description of hospital based AHF treatment Inter and intra-observer agreement 
Trajectory of B-line clearance 
Assess B-line clearance by sub-group/HF 
phenotype  
 
DAOOH - Days alive and out of hospital  
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Figure 3. Pictorial representation of the 8-zone scanning protocol. 
 
 
Figure 4. LUS image of B-lines taken from Right Zone 1. B-line score for this image is 10. 
 
 
 
